title: Human Lyme arthritis and the immunoglobulin G antibody response to the 37-kilodalton arthritis-related protein of Borrelia burgdorferi.
abstract: In Borrelia burgdorferi-infected C3H-scid mice, antiserum to a differentially expressed, 37-kDa spirochetal outer-surface protein, termed arthritis-related protein (Arp), has been shown to prevent or reduce the severity of arthritis. In this study, we determined the immunoglobulin G (IgG) antibody responses to this spirochetal protein in single serum samples from 124 antibiotic-treated human patients with early or late manifestations of Lyme disease and in serial serum samples from 20 historic, untreated patients who were followed longitudinally from early infection through the period of arthritis. These 20 patients were representative of the spectrum of the severity and duration of Lyme arthritis. Among the 124 antibiotic-treated patients, 53% with culture-proven erythema migrans (EM) had IgG responses to recombinant glutathione S-transferase (GST)-Arp, as did 59% of the patients with facial palsy and 68% of those with Lyme arthritis. In addition, 75 to 80% of the 20 past, untreated patients had reactivity with this protein when EM was present, during initial episodes of joint pain, or during the maximal period of arthritis. There was no association at any of these three time points between GST-Arp antibody levels and the severity of the maximal attack of arthritis or the total duration of arthritis. Thus, after the first several weeks of infection, 60 to 80% of patients had IgG antibody responses to GST-Arp, but this response did not correlate with the severity or duration of Lyme arthritis.
authors.affiliation: Massachusetts General Hospital, 55 Fruit St., CNY 149/8301, Boston, MA 02114, USA.
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Salazar
authors.forename: Monika
authors.initials: M
authors.lastname: Rothemich
authors.forename: Elise E
authors.initials: EE
authors.lastname: Drouin
authors.forename: Lisa
authors.initials: L
authors.lastname: Glickstein
authors.forename: Allen C
authors.initials: AC
authors.lastname: Steere
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood; D001426:Bacterial Proteins / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D025065:Borrelia burgdorferi / Q000276:immunology*; D005158:Facial Paralysis / Q000276:immunology; D005982:Glutathione Transferase / Q000235:genetics / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008193:Lyme Disease / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D012720:Severity of Illness Index
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins; D005982:Glutathione Transferase